IP Library › Granted Patent US 12,383,710
Granted Patent B2
US 12,383,710 · App. 18/645,654 · Granted Aug 12, 2025

Drug-coated balloon catheters for body lumens

Inventors: Lixiao Wang (Henderson, NV); Peter Barnett (Shakopee, MN); David Hendrickson (Coon Rapids, MN)
Assignee: Urotronic, Inc.
A61M25/10A61L29/16A61L2300/416A61M2025/105A61M2025/1059A61M2025/1068A61M2210/105A61M2210/1057A61M2210/106A61M2210/1064A61M2210/1085A61M2210/1089
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,710
App. No.
18/645,654
Granted
Aug 12, 2025
Kind
B2
Abstract

Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

Claims (47)

1. A drug-coated balloon catheter comprising:

an elongated balloon; and

a coating layer overlaying an exterior surface of the balloon, the coating layer comprising an initial drug load of a therapeutic agent comprising paclitaxel, and

at least one additive comprising a sugar derivative, a chemical compound with one or more ester moieties, or a combination thereof;

wherein the coating layer directly contacts the exterior surface of the balloon; and

wherein a soaking procedure for treating a target site in a body lumen with the drug-coated balloon catheter is sufficient for the coating layer to release 37 wt % to 97 wt % of the initial drug load of the therapeutic agent from the coating layer, wherein the soaking procedure consists of

passing the drug-coated balloon catheter through an introducer sheath into a cylindrical vessel, the cylindrical vessel comprising 0.9% saline at 37° C.,

soaking the drug-coated balloon catheter in the saline in the cylindrical vessel for 1 minute,

inflating the drug-coated balloon catheter for 1 minute, and

withdrawing the drug-coated balloon catheter from the cylinder.

2. The drug-coated balloon of claim 1 , wherein the at least one additive comprises the sugar derivative.

3. The drug-coated balloon of claim 1 , wherein the at least one additive comprises the chemical compound with one or more ester moieties.

4. The drug-coated balloon catheter of claim 1 , wherein the elongated balloon has a length of 20 mm to 160 mm.

5. The drug-coated balloon catheter of claim 1 , wherein the coating layer has a weight ratio of the therapeutic agent to the one or more additives of 0.05:1 to 20:1.

6. A drug-coated balloon catheter comprising:

an elongated balloon; and

a coating layer overlaying an exterior surface of the balloon, the coating layer comprising

an initial drug load of a therapeutic agent comprising paclitaxel, and

at least one additive comprising a sugar derivative, a chemical compound with one or more ester moieties, or a combination thereof;

wherein the coating layer directly contacts the exterior surface of the balloon; and

wherein flushing a target site in a body lumen and holding the drug-coated balloon catheter in position at the target site to hydrate the coating layer is sufficient for the body lumen tissue at the target site to have a concentration of the therapeutic agent of 0.083 μg/g to 582 μg/g at 1 day.

7. The drug-coated balloon catheter of claim 6 , wherein the treatment procedure is sufficient for the coating layer to release the therapeutic agent from the coating layer into body lumen tissue at the target site such that the body lumen tissue at the target site has a concentration of the therapeutic agent of 0.003 μg/g to 62 μg/g at 7 days.

8. The drug-coated balloon catheter of claim 6 , wherein the treatment procedure is sufficient for the coating layer to release the therapeutic agent from the coating layer into body lumen tissue at the target site such that the body lumen tissue at the target site has a concentration of the therapeutic agent of 0.025 μg/g to 33 μg/g at 28 days.

9. The drug-coated balloon catheter of claim 6 , wherein the initial drug load of the therapeutic agent is from 1 microgram to 20 micrograms per square millimeter of the balloon at the nominal diameter of the balloon.

10. The drug-coated balloon of claim 6 , wherein the at least one additive comprises the sugar derivative.

11. The drug-coated balloon of claim 6 , wherein the at least one additive comprises the chemical compound with one or more ester moieties.

12. The drug-coated balloon catheter of claim 6 , wherein the elongated balloon has a length of 20 mm to 160 mm.

13. A drug-coated balloon catheter comprising:

an elongated balloon; and

a coating layer overlaying an exterior surface of the balloon, the coating layer comprising

an initial drug load of a therapeutic agent comprising paclitaxel, and

at least one additive comprising a sugar derivative, a chemical compound with one or more ester moieties, or a combination thereof,

wherein the coating layer directly contacts the exterior surface of the balloon; and

wherein flushing a target site in a body lumen and holding the drug-coated balloon catheter in position at the target site to hydrate the coating layer is sufficient for the coating layer to release more than 30 wt % of the initial drug load of the therapeutic agent from the coating layer to the target site in the body lumen.

14. The drug-coated balloon of claim 13 , wherein the at least one additive comprises the sugar derivative.

15. The drug-coated balloon of claim 13 , wherein the at least one additive comprises the chemical compound with one or more ester moieties.

16. The drug-coated balloon catheter of claim 13 , wherein the elongated balloon has a length of 20 mm to 160 mm.

17. A drug-coated balloon catheter comprising:

an elongated balloon; and

a coating layer overlaying an exterior surface of the balloon, the coating layer comprising

an initial drug load of a therapeutic agent comprising paclitaxel, and

at least one additive comprising a sugar derivative, a chemical compound with one or more ester moieties, or a combination thereof;

wherein the coating layer directly contacts the exterior surface of the balloon; and

wherein flushing a target site in a body lumen and holding the drug-coated balloon catheter in position at the target site to hydrate the coating layer is sufficient for the coating layer to release 0.1% to 25% of the initial drug load of the therapeutic agent from the coating layer to a body lumen wall at the target site in the body lumen.

18. The drug-coated balloon of claim 17 , wherein the at least one additive comprises the sugar derivative.

19. The drug-coated balloon of claim 17 , wherein the at least one additive comprises the chemical compound with one or more ester moieties.

20. The drug-coated balloon catheter of claim 17 , wherein the elongated balloon has a length of 20 mm to 160 mm.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2024
From: WANG, LIXIAO; BARNETT, PETER; HENDRICKSON, DAVID
To: UROTRONIC, INC.
Reel/Frame 067224/0001 →
Continuity (4)
Continuation 17255701
Provisional Application 62859396 · Jun 10, 2019
Provisional Application 62809048 · Feb 22, 2019
Related Publication 20240269439A1 · Aug 15, 2024
References Cited (400)
US 1686437A · Thomas et al. · 1928 [cited by applicant]
US 5171299A · Heitzmann et al. · 1992 [cited by applicant]
US 5263931A · Miller · 1993 [cited by applicant]
US 5312430A · Rosenbluth et al. · 1994 [cited by applicant]
US 5314443A · Rudnick · 1994 [cited by applicant]
US 5419763A · Hildebrand · 1995 [cited by applicant]
US 5423755A · Kesten et al. · 1995 [cited by applicant]
US 5562620A · Klein et al. · 1996 [cited by applicant]
US 5718684A · Gupta · 1998 [cited by applicant]
US 5752522A · Murphy · 1998 [cited by applicant]
US 5904648A · Arndt et al. · 1999 [cited by applicant]
US 6059713A · Urick et al. · 2000 [cited by applicant]
US 6268390B1 · Kunz · 2001 [cited by applicant]
US 6306421B1 · Kunz et al. · 2001 [cited by applicant]
US 6403635B1 · Kinsella et al. · 2002 [cited by applicant]
US 6488653B1 · Lombardo · 2002 [cited by applicant]
US 6495579B1 · Hunter · 2002 [cited by applicant]
US 6515009B1 · Kunz et al. · 2003 [cited by applicant]
US 6530948B1 · Vrba · 2003 [cited by applicant]
US 6579221B1 · Peterson · 2003 [cited by applicant]
US 6663881B2 · Kunz et al. · 2003 [cited by applicant]
US 6730064B2 · Ragheb et al. · 2004 [cited by applicant]
US 7803149B2 · Bates et al. · 2010 [cited by applicant]
US 7811622B2 · Bates et al. · 2010 [cited by applicant]
US 7882841B2 · Aljuri · 2011 [cited by examiner]
US 8052668B2 · Sih · 2011 [cited by applicant]
US 8092864B2 · Isch et al. · 2012 [cited by applicant]
US 8241249B2 · Wang · 2012 [cited by applicant]
US 8244344B2 · Wang · 2012 [cited by applicant]
US 8257305B2 · Speck et al. · 2012 [cited by applicant]
US 8366660B2 · Wang · 2013 [cited by applicant]
US 8366662B2 · Wang · 2013 [cited by applicant]
US 8403910B2 · Wang · 2013 [cited by applicant]
US 8404300B2 · Wang · 2013 [cited by applicant]
US 8414525B2 · Wang · 2013 [cited by applicant]
US 8414526B2 · Wang · 2013 [cited by applicant]
US 8414909B2 · Wang · 2013 [cited by applicant]
US 8414910B2 · Wang · 2013 [cited by applicant]
US 8425459B2 · Wang · 2013 [cited by applicant]
US 8430055B2 · Wang et al. · 2013 [cited by applicant]
US 8439868B2 · Speck et al. · 2013 [cited by applicant]
US 8557272B2 · Zhao · 2013 [cited by applicant]
US 8586125B2 · Hossainy et al. · 2013 [cited by applicant]
US 8673387B2 · Bates et al. · 2014 [cited by applicant]
US 8722132B2 · Labrecque et al. · 2014 [cited by applicant]
US 9066990B2 · Speck et al. · 2015 [cited by applicant]
US 9242081B2 · Drasler et al. · 2016 [cited by applicant]
US 9728840B2 · Shi et al. · 2017 [cited by applicant]
US 10245419B2 · Drasler et al. · 2019 [cited by applicant]
US 10668188B2 · Wang · 2020 [cited by applicant]
US 10675386B2 · Wang · 2020 [cited by applicant]
US 10806830B2 · Wang et al. · 2020 [cited by applicant]
US 10850076B2 · Wang et al. · 2020 [cited by applicant]
US 10881839B2 · Wang et al. · 2021 [cited by applicant]
US 10888640B2 · Wang et al. · 2021 [cited by applicant]
US 10898700B2 · Wang et al. · 2021 [cited by applicant]
US 10987451B2 · Wang · 2021 [cited by examiner]
US 10994103B2 · Wang et al. · 2021 [cited by applicant]
US 10994104B2 · Wang et al. · 2021 [cited by applicant]
US 11439801B2 · Wang et al. · 2022 [cited by applicant]
US 11471655B2 · Wang et al. · 2022 [cited by applicant]
US 11471656B2 · Wang et al. · 2022 [cited by applicant]
US 11484628B2 · Wang et al. · 2022 [cited by applicant]
US 11504450B2 · Wang et al. · 2022 [cited by applicant]
US 11648337B2 · Wang · 2023 [cited by examiner]
US 11648338B2 · Wang · 2023 [cited by examiner]
US 11730864B2 · Wang et al. · 2023 [cited by applicant]
US 11826532B2 · Wang et al. · 2023 [cited by applicant]
US 11826533B2 · Wang et al. · 2023 [cited by applicant]
US 11904072B2 · Wang et al. · 2024 [cited by applicant]
US 11925729B2 · Wang et al. · 2024 [cited by applicant]
US 11938287B2 · Wang et al. · 2024 [cited by applicant]
US 12005206B2 · Wang et al. · 2024 [cited by applicant]
US 12102737B2 · Wang et al. · 2024 [cited by applicant]
US 12115286B2 · Wang · 2024 [cited by examiner]
US 12168108B2 · Wang et al. · 2024 [cited by applicant]
US 20030203991A1 · Schottman et al. · 2003 [cited by applicant]
US 20040098019A1 · Tomaschko et al. · 2004 [cited by applicant]
US 20040144387A1 · Amar · 2004 [cited by applicant]
US 20040267355A1 · Scott et al. · 2004 [cited by applicant]
US 20050054978A1 · Segal et al. · 2005 [cited by applicant]
US 20050196518A1 · Stenzel · 2005 [cited by applicant]
US 20050249770A1 · Hunter · 2005 [cited by applicant]
US 20060083768A1 · Labrecque et al. · 2006 [cited by applicant]
US 20070005094A1 · Eaton et al. · 2007 [cited by applicant]
US 20070009692A1 · Wang et al. · 2007 [cited by applicant]
US 20070027523A1 · Toner et al. · 2007 [cited by applicant]
US 20070031371A1 · Kozlowski · 2007 [cited by applicant]
US 20070088255A1 · Toner et al. · 2007 [cited by applicant]
US 20070260178A1 · Skerven et al. · 2007 [cited by applicant]
US 20080025952A1 · Scheule et al. · 2008 [cited by applicant]
US 20080113035A1 · Hunter · 2008 [cited by applicant]
US 20080118544A1 · Wang · 2008 [cited by applicant]
US 20080175887A1 · Wang · 2008 [cited by applicant]
US 20080183132A1 · Davies et al. · 2008 [cited by applicant]
US 20080245375A1 · Trudel · 2008 [cited by applicant]
US 20080255508A1 · Wang · 2008 [cited by applicant]
US 20080255509A1 · Wang · 2008 [cited by applicant]
US 20080255510A1 · Wang · 2008 [cited by applicant]
US 20080276935A1 · Wang · 2008 [cited by applicant]
US 20080294237A1 · Chu · 2008 [cited by applicant]
US 20090018565A1 · To et al. · 2009 [cited by applicant]
US 20090028920A1 · Hodges · 2009 [cited by applicant]
US 20090171241A1 · Garcia et al. · 2009 [cited by applicant]
US 20090283206A1 · Eskaros et al. · 2009 [cited by applicant]
US 20100015200A1 · McClain et al. · 2010 [cited by applicant]
US 20100030183A1 · Toner et al. · 2010 [cited by applicant]
US 20100049182A1 · Ryan et al. · 2010 [cited by applicant]
US 20100055294A1 · Wang et al. · 2010 [cited by applicant]
US 20100076402A1 · Mazzone et al. · 2010 [cited by applicant]
US 20100198150A1 · Michal et al. · 2010 [cited by applicant]
US 20100209472A1 · Wang · 2010 [cited by applicant]
US 20100233228A1 · Speck · 2010 [cited by applicant]
US 20100285085A1 · Stankus et al. · 2010 [cited by applicant]
US 20110008260A1 · Flanagan · 2011 [cited by applicant]
US 20110015664A1 · Kangas et al. · 2011 [cited by applicant]
US 20110098683A1 · Wiita et al. · 2011 [cited by applicant]
US 20110144578A1 · Pacetti et al. · 2011 [cited by applicant]
US 20110159169A1 · Wang · 2011 [cited by applicant]
US 20110160575A1 · Beyar et al. · 2011 [cited by applicant]
US 20110160658A1 · Wang · 2011 [cited by applicant]
US 20110160660A1 · Wang · 2011 [cited by applicant]
US 20110166548A1 · Wang · 2011 [cited by applicant]
US 20110196340A1 · Barry et al. · 2011 [cited by applicant]
US 20110295200A1 · Speck et al. · 2011 [cited by applicant]
US 20110300221A1 · Kunz et al. · 2011 [cited by applicant]
US 20120029426A1 · Wang · 2012 [cited by applicant]
US 20120035530A1 · Wang · 2012 [cited by applicant]
US 20120109105A1 · Cambronne · 2012 [cited by applicant]
US 20120130174A1 · Simmons · 2012 [cited by applicant]
US 20120172796A1 · Chappa · 2012 [cited by applicant]
US 20120231037A1 · Levi et al. · 2012 [cited by applicant]
US 20120239001A1 · Barry et al. · 2012 [cited by applicant]
US 20120296274A1 · Slager · 2012 [cited by applicant]
US 20120302954A1 · Zhao · 2012 [cited by applicant]
US 20120316633A1 · Flanagan et al. · 2012 [cited by applicant]
US 20130197434A1 · Wang · 2013 [cited by applicant]
US 20130197436A1 · Wang · 2013 [cited by applicant]
US 20130231638A1 · Speck et al. · 2013 [cited by applicant]
US 20130245058A1 · Hoffmann et al. · 2013 [cited by applicant]
US 20130253466A1 · Campbell et al. · 2013 [cited by applicant]
US 20130253475A1 · Wang · 2013 [cited by applicant]
US 20130261603A1 · Wang · 2013 [cited by applicant]
US 20130304029A1 · Barry et al. · 2013 [cited by applicant]
US 20140005541A1 · Bates et al. · 2014 [cited by applicant]
US 20140031843A1 · Rottenberg et al. · 2014 [cited by applicant]
US 20140228751A1 · Speck et al. · 2014 [cited by applicant]
US 20140228752A1 · Speck et al. · 2014 [cited by applicant]
US 20140378896A1 · Venturelli · 2014 [cited by applicant]
US 20150231375A1 · Kubo et al. · 2015 [cited by applicant]
US 20150273117A1 · Wang · 2015 [cited by examiner]
US 20160038648A1 · Gemborys · 2016 [cited by applicant]
US 20160082159A1 · Orlowski · 2016 [cited by applicant]
US 20160250388A1 · Wang · 2016 [cited by applicant]
US 20160338793A1 · Shohat et al. · 2016 [cited by applicant]
US 20170028105A1 · Ahlering et al. · 2017 [cited by applicant]
US 20170086929A1 · Moll et al. · 2017 [cited by applicant]
US 20170274179A1 · Sullivan et al. · 2017 [cited by applicant]
US 20180104383A1 · Wang et al. · 2018 [cited by applicant]
US 20190015639A1 · Wang et al. · 2019 [cited by applicant]
US 20190015640A1 · Wang et al. · 2019 [cited by applicant]
US 20190167854A1 · Wang · 2019 [cited by applicant]
US 20190344053A1 · Wang et al. · 2019 [cited by applicant]
US 20190374685A1 · Wang et al. · 2019 [cited by applicant]
US 20200254148A1 · Wang · 2020 [cited by applicant]
US 20200360571A1 · Wang et al. · 2020 [cited by applicant]
US 20210052862A1 · Wang et al. · 2021 [cited by applicant]
US 20210052863A1 · Wang et al. · 2021 [cited by applicant]
US 20210052864A1 · Wang et al. · 2021 [cited by applicant]
US 20210052865A1 · Wang et al. · 2021 [cited by applicant]
US 20210077666A1 · Wang et al. · 2021 [cited by applicant]
US 20210113742A1 · Wang et al. · 2021 [cited by applicant]
US 20210113823A1 · Wang et al. · 2021 [cited by applicant]
US 20210205502A1 · Wang et al. · 2021 [cited by applicant]
US 20210228780A1 · Wang et al. · 2021 [cited by applicant]
US 20210361918A1 · Wang et al. · 2021 [cited by applicant]
US 20220323653A1 · Wang et al. · 2022 [cited by applicant]
US 20220323732A1 · Wang et al. · 2022 [cited by applicant]
US 20230001163A1 · Wang et al. · 2023 [cited by applicant]
US 20230020891A1 · Wang et al. · 2023 [cited by applicant]
US 20230050453A1 · Wang et al. · 2023 [cited by applicant]
US 20230149602A1 · Wang et al. · 2023 [cited by applicant]
US 20230149672A1 · Wang et al. · 2023 [cited by applicant]
US 20230173240A1 · Wang et al. · 2023 [cited by applicant]
US 20230347022A1 · Wang et al. · 2023 [cited by applicant]
US 20230372593A1 · Wang et al. · 2023 [cited by applicant]
US 20240042183A1 · Wang et al. · 2024 [cited by applicant]
US 20240042184A1 · Wang et al. · 2024 [cited by applicant]
US 20240165303A1 · Wang et al. · 2024 [cited by applicant]
US 20240173525A1 · Wang et al. · 2024 [cited by applicant]
US 20240416013A1 · Wang et al. · 2024 [cited by applicant]
CN 101273926A · 2008 [cited by applicant]
CN 101610798A · 2009 [cited by applicant]
CN 101631514A · 2010 [cited by applicant]
CN 102357278A · 2012 [cited by applicant]
CN 202191333U · 2012 [cited by applicant]
CN 102573946A · 2012 [cited by applicant]
CN 103007425A · 2013 [cited by applicant]
CN 203138758U · 2013 [cited by applicant]
CN 103328033A · 2013 [cited by applicant]
CN 103458954A · 2013 [cited by applicant]
CN 103930158A · 2014 [cited by applicant]
CN 104780859A · 2015 [cited by applicant]
CN 104936629A · 2015 [cited by applicant]
CN 107088258A · 2017 [cited by applicant]
CN 107635593A · 2018 [cited by applicant]
CN 109414528A · 2019 [cited by applicant]
CN 111166942A · 2020 [cited by applicant]
CN 113727750A · 2021 [cited by applicant]
CN 109414528B · 2022 [cited by applicant]
CN 115227880A · 2022 [cited by applicant]
CN 118454075 · 2024 [cited by applicant]
CN 113727750 · 2024 [cited by applicant]
CN 119303213A · 2025 [cited by applicant]
EP 0474906A1 · 1992 [cited by applicant]
EP 1135165A1 · 2001 [cited by applicant]
EP 1143968B1 · 2003 [cited by applicant]
EP 1384840A1 · 2004 [cited by applicant]
EP 1539266B1 · 2008 [cited by applicant]
EP 2292225B1 · 2012 [cited by applicant]
EP 2098230B1 · 2012 [cited by applicant]
EP 2262547B1 · 2013 [cited by applicant]
EP 2324866B1 · 2014 [cited by applicant]
EP 2324867B1 · 2014 [cited by applicant]
EP 2531229B1 · 2014 [cited by applicant]
EP 2451496B1 · 2015 [cited by applicant]
EP 2911711 · 2015 [cited by applicant]
EP 3442612B1 · 2020 [cited by applicant]
JP H06343597A · 1994 [cited by applicant]
JP WO0032238 · 2000 [cited by applicant]
JP 2001238953A · 2001 [cited by applicant]
JP 2007229499A · 2007 [cited by applicant]
JP 2008541835A · 2008 [cited by applicant]
JP 2009022759A · 2009 [cited by applicant]
JP 2010540159A · 2010 [cited by applicant]
JP 2011024953A · 2011 [cited by applicant]
JP 2012502690A · 2012 [cited by applicant]
JP 2013001415A · 2013 [cited by applicant]
JP 2013523209A · 2013 [cited by applicant]
JP 2014523790A · 2014 [cited by applicant]
JP 2015536709A · 2015 [cited by applicant]
JP 2016503330A · 2016 [cited by applicant]
JP 2016036730A · 2016 [cited by applicant]
JP 2016518200A · 2016 [cited by applicant]
JP 2017507741A · 2017 [cited by applicant]
JP 2018517454A · 2018 [cited by applicant]
JP 2019137680A · 2019 [cited by applicant]
JP 2019523032A · 2019 [cited by applicant]
JP 2019218354A · 2019 [cited by applicant]
JP 2020049269A · 2020 [cited by applicant]
JP 2020075155A · 2020 [cited by applicant]
JP 6833218B2 · 2021 [cited by applicant]
JP 2021072908A · 2021 [cited by applicant]
JP 2022521000A · 2022 [cited by applicant]
JP 2023052847A · 2023 [cited by applicant]
JP 2023082069A · 2023 [cited by applicant]
JP 7429948B2 · 2024 [cited by applicant]
JP 2024110887 · 2024 [cited by applicant]
JP 2025011111A · 2025 [cited by applicant]
WO WO9728840A1 · 1997 [cited by applicant]
WO WO9803218A1 · 1998 [cited by examiner]
WO WO0025848A2 · 2000 [cited by applicant]
WO WO2011147407A2 · 2001 [cited by applicant]
WO WO2006130194A2 · 2006 [cited by applicant]
WO WO2009051614A1 · 2009 [cited by examiner]
WO WO2011008393A2 · 2011 [cited by applicant]
WO WO2011119159A1 · 2011 [cited by applicant]
WO WO2012122023A2 · 2012 [cited by applicant]
WO WO2013015941A1 · 2013 [cited by applicant]
WO WO2013086698A1 · 2013 [cited by applicant]
WO WO2013110158A1 · 2013 [cited by applicant]
WO WO2014066085A1 · 2014 [cited by applicant]
WO WO2014087395A1 · 2014 [cited by applicant]
WO WO2014177678A1 · 2014 [cited by applicant]
WO WO2015136106A1 · 2015 [cited by applicant]
WO WO2016018923A1 · 2016 [cited by applicant]
WO WO2016073294A1 · 2016 [cited by applicant]
WO WO2016118923A1 · 2016 [cited by applicant]
WO WO2016172343A1 · 2016 [cited by applicant]
WO WO2018204782A1 · 2018 [cited by applicant]
WO WO2020172560A1 · 2020 [cited by applicant]
Jun. 19, 2020 declaration for U.S. Appl. No. 16/519,677. (Year: 2020) [cited by examiner]
“European Application Serial No. 20712766.3, Communication Pursuant to Article 94(3) EPC mailed Apr. 23, 2024”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 18/214,131, Response filed May 9, 2024 to Non Final Office Action mailed Feb. 15, 2024”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 17/843,150, Response filed May 9, 2024 to Non Final Office Action mailed Feb. 15, 2024”, 8 pgs. [cited by applicant]
“Japanese Application Serial No. 2021-549230, Examiners Decision of Final Refusal mailed May 21, 2024”, w English translation, 3 pgs. [cited by applicant]
“U.S. Appl. No. 18/379,505, Non Final Office Action mailed May 23, 2024”, 6 pgs. [cited by applicant]
“Chinese Application Serial No. 202080030597.8, Response filed May 22, 2024 to Office Action mailed Mar. 23, 2024”, w current English claims, 15 pgs. [cited by applicant]
“U.S. Appl. No. 18/214,131, Notice of Allowance mailed Jun. 5, 2024”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 17/843,150, Notice of Allowance mailed Jun. 6, 2024”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 18/214,131, Corrected Notice of Allowability mailed Jun. 13, 2024”, 8 pgs. [cited by applicant]
“Japanese Application Serial No. 2023-014484, Response filed Jul. 10, 2024 to Decision of Rejection mailed Mar. 12, 2024”, w current English claims, 16 pgs. [cited by applicant]
“European Application Serial No. 20712766.3, Response filed Jul. 18, 2024 to Communication Pursuant to Article 94(3) EPC mailed Apr. 23, 2024”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 18/379,505, Response filed Aug. 14, 2024 to Non Final Office Action mailed May 23, 2024”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 18/219,837, Non Final Office Action mailed Aug. 29, 2024”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 18/431,234, Non Final Office Action mailed Aug. 29, 2024”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 18/436,480, Non Final Office Action mailed Aug. 29, 2024”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 18/379,505, Notice of Allowance mailed Aug. 29, 2024”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 17/843,150, Corrected Notice of Allowability mailed Sep. 13, 2024”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 18/379,517, Non Final Office Action mailed Sep. 30, 2024”, 18 pgs. [cited by applicant]
“Japanese Application Serial No. 2021-549230, Response filed Sep. 20, 2024 to Examiners Decision of Final Refusal mailed May 21, 2024”, w claims, 10 pgs. [cited by applicant]
Vaughan, W C, “Review of balloon sinuplasty”, Curr. Opin. Otolarngol Head Neck Surg., 16 pp. 2-9, (2008), 8 pgs. [cited by applicant]
“37 C.F.R. section 1.132 Declaration for U.S. Appl. No. 16/135,436, filed Jan. 13, 2020”, (2020), 5 pgs. [cited by applicant]
“Acetic Acid”, ChemSpider, Accessed online on Mar. 13, 2021 at <https://www.chemspider.com/Search.aspx?q=acetic+acidl>, (2021), 2 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Advisory Action mailed Jul. 18, 2018”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Corrected Notice of Allowability mailed May 5, 2020”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Examiner Interview Summary mailed Feb. 12, 2020”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Final Office Action mailed Apr. 2, 2018”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Final Office Action mailed May 3, 2017”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Final Office Action mailed Aug. 9, 2019”, 20 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Non Final Office Action mailed Jan. 7, 2020”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Non Final Office Action mailed Jan. 28, 2019”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Non Final Office Action mailed Sep. 29, 2017”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Non Final Office Action mailed Oct. 6, 2016”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Notice of Allowance mailed Apr. 22, 2020”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Preliminary Amendment filed Jul. 28, 2015”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Feb. 7, 2020 to Non Final Office Action mailed Jan. 7, 2020”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Apr. 16, 2019 to Non Final Office Action mailed Jan. 28, 2019”, 29 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Jun. 1, 2018 to Final Office Action mailed Apr. 2, 2018”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Jul. 27, 2017 to Final Office Action mailed May 3, 2017”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Aug. 1, 2018 to Advisory Action mailed Jul. 18, 2018 and Final Office Action mailed Apr. 2, 2018”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Aug. 24, 2016 to Restriction Requirement mailed Jul. 12, 2016”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Dec. 3, 2019 to Final Office Action mailed Aug. 9, 2019”, 32 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Dec. 15, 2017 to Non Final Office Action mailed Sep. 29, 2017”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Response filed Dec. 28, 2016 to Non Final Office Action mailed Oct. 6, 2016”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,327, Restriction Requirement mailed Jul. 12, 2016”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Corrected Notice of Allowability mailed Nov. 30, 2020”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Final Office Action mailed May 15, 2020”, 25 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Non Final Office Action mailed Nov. 18, 2019”, 22 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Notice of Allowance mailed Sep. 30, 2020”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Notice of Non-Responsive Amendment mailed Jul. 1, 2019”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Response filed Feb. 10, 2020 to Non Final Office Action mailed Nov. 18, 2019”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Response filed Mar. 20, 2019 to Restriction Requirement mailed Feb. 8, 2019”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Response filed Jul. 9, 2019 to Non-Responsive Amendment mailed Jul. 1, 2019 & Restriction Requirement mailed Feb. 8, 2019”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Response filed Jul. 14, 2020 to Final Office Action mailed May 15, 2020”, 23 pgs. [cited by applicant]
“U.S. Appl. No. 15/568,614, Restriction Requirement mailed Feb. 8, 2019”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Corrected Notice of Allowability mailed Sep. 11, 2020”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Examiner Interview Summary mailed Apr. 8, 2020”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Final Office Action mailed Nov. 29, 2019”, 41 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Non Final Office Action mailed Mar. 5, 2020”, 48 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Non Final Office Action mailed Jul. 29, 2019”, 38 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Notice of Allowance mailed Jul. 10, 2020”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Notice of Non-Responsive Amendment mailed Mar. 8, 2019”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Response filed Jan. 13, 2020 to Final Office Action mailed Nov. 29, 2019”, 22 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Response filed Mar. 28, 2019 to Notice of Non-Responsive Amendment mailed Mar. 8, 2019”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Response filed Apr. 6, 2020 to Non Final Office Action mailed Mar. 5, 2020”, 21 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Response filed Aug. 21, 2019 to Non Final Office Action mailed Jul. 29, 2019”, 18 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Response filed Nov. 14, 2018 to Restriction Requirement mailed Nov. 2, 2018”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,436, Restriction Requirement mailed Nov. 2, 2018”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Corrected Notice of Allowability mailed Nov. 30, 2020”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Examiner Interview Summary mailed May 19, 2020”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Final Office Action mailed Aug. 21, 2020”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Final Office Action mailed Nov. 29, 2019”, 43 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Non Final Office Action mailed Mar. 19, 2020”, 56 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Non Final Office Action mailed Jul. 30, 2019”, 40 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Notice of Allowance mailed Oct. 7, 2020”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Notice of Non Responsive Amendment mailed Mar. 8, 2019”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Response filed Jan. 13, 2020 to Final Office Action mailed Nov. 29, 2019”, 27 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Response filed Mar. 28, 2019 to Notice of Non Responsive Amendment mailed Mar. 8, 2019”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Response filed May 15, 2020 to Non Final Office Action mailed Mar. 19, 2020”, 29 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Response filed Sep. 4, 2020 to Final Office Action mailed Aug. 21, 2020”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Response filed Nov. 14, 2018 to Restriction Requirement mailed Nov. 2, 2018”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Response filed Aug. 21, 2019 to Non Final Office Action mailed Jul. 30, 2019”, 23 pgs. [cited by applicant]
“U.S. Appl. No. 16/135,472, Restriction Requirement mailed Nov. 2, 2018”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Corrected Notice of Allowability mailed May 13, 2020”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Final Office Action mailed Mar. 30, 2020”, 18 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Final Office Action mailed Jun. 14, 2019”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Non Final Office Action mailed Mar. 22, 2019”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Non Final Office Action mailed Nov. 18, 2019”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Notice of Allowance mailed Apr. 22, 2020”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Response filed Feb. 13, 2020 to Non Final Office Action mailed Nov. 18, 2019”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Response filed Mar. 31, 2020 to Final Office Action mailed Mar. 30, 2020”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Response Filed Apr. 24, 2019 to Non-Final Office Action Mailed Mar. 22, 2019”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/267,434, Response filed Sep. 11, 2019 to Final Office Action mailed Jun. 14, 2019”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,677, Corrected Notice of Allowability mailed Nov. 30, 2020”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,677, Non Final Office Action mailed Mar. 19, 2020”, 31 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,677, Notice of Allowance mailed Sep. 21, 2020”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,677, Response filed Jun. 19, 2020 to Non Final Office Action mailed Mar. 19, 2020”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,677, Response filed Dec. 13, 2019 to Restriction Requirement mailed Nov. 20, 2019”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,677, Restriction Requirement mailed Nov. 20, 2019”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,720, Final Office Action mailed Aug. 21, 2020”, 23 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,720, Non Final Office Action mailed Feb. 6, 2020”, 23 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,720, Notice of Allowance mailed Oct. 21, 2020”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,720, Response filed May 6, 2020 to Non Final Office Action mailed Feb. 6, 2020”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,720, Response filed Sep. 4, 2020 to Final Office Action mailed Aug. 21, 2020”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,720, Response filed Oct. 31, 2019 to Restriction Requirement mailed Oct. 18, 2019”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/519,720, Restriction Requirement mailed Oct. 18, 2019”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/864,373, Examiner Interview Summary mailed Jul. 12, 2021”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/864,373, Final Office Action mailed May 25, 2021”, 44 pgs. [cited by applicant]
“U.S. Appl. No. 16/864,373, Non Final Office Action mailed Mar. 18, 2021”, 32 pgs. [cited by applicant]
“U.S. Appl. No. 16/864,373, Response filed Apr. 6, 2021 to Non Final Office Action mailed Mar. 18, 2021”, 25 pgs. [cited by applicant]
“U.S. Appl. No. 16/864,373, Response filed Dec. 10, 2020 to Restriction Requirement mailed Nov. 17, 2020”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/864,373, Restriction Requirement mailed Nov. 17, 2020”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,683, Corrected Notice of Allowability mailed Mar. 17, 2021”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,683, Non Final Office Action mailed Oct. 29, 2020”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,683, Notice of Allowance mailed Jan. 4, 2021”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,683, Response filed Dec. 4, 2020 to Non Final Office Action mailed Oct. 29, 2020”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,088, Corrected Notice of Allowability mailed Jul. 12, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,088, Non Final Office Action mailed Mar. 3, 2022”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/080,088, Notice of Allowance mailed Jun. 14, 2022”, 11 pgs. [cited by applicant]